Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImmuRaid-CEA data

A Phase III study sponsored by IMMU (Morris Plains, N.J.) and reported

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE